Anaplastic lymphoma kinase (ALK) is an attractive therapeutic target for the treatment of non-small cell lung cancer (NSCLC). Within our ALK drug discovery program, we identified novel deuterated 2,4-diarylamino pyrimidine compounds as potent ALK inhibitors. The compound 11 showed better in vitro activity and in vivo efficacy with good pharmacokinetic profile. In vivo efficacy of compound 11 was better than standard drug ceritinib in NCI-H2228 xenograft mice model.
Keywords: ALK; Anaplastic lymphoma kinase; Ceritinib; Deuterated drug; Inhibitor; Kinase; NSCLC; Non-small cell lung cancer.
Copyright © 2019 Elsevier Ltd. All rights reserved.